Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OTC | P00480 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64149 | 1.00 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL432790 | 1.00 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL6369985 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL28449339 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL25670261 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL5971277 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL8919761 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL27243097 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL3438660 | 0.94 | GSR (0.54) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL31688818 | 0.94 | GSR (0.54) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| CN-116559343-A | Screening and application of tuberculosis urine metabolic markers | 首都医科大学附属北京胸科医院 | 2023-08-08 | — | — | CN | claimed |
| WO-2023089542-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2023-05-25 | — | — | WO | claimed |
| EP-4175970-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2023-05-10 | — | — | EP | claimed |
| WO-2022149610-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | ペプチドリーム株式会社 | 2022-07-14 | — | — | WO | claimed |
| WO-2022000043-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2022-01-06 | — | — | WO | claimed |
| CN-113769108-A | Conjugates of cysteine engineered antibodies | 伊缪诺金公司 | 2021-12-10 | — | — | CN | claimed |
| US-9796766-B2 | Potent and selective inhibitors of NAV1.3 and NAV1.7 | AMGEN INC. (US) | 2017-10-24 | — | — | US | claimed |
| US-20160304570-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2016-10-20 | — | — | US | claimed |
| US-9340590-B2 | Potent and selective inhibitors of NaV1.3 and NaV1.7 | AMGEN INC. (US) | 2016-05-17 | — | — | US | claimed |
| WO-2014134457-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2014-03-13 | — | — | US | claimed |
| EP-2686340-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | Amgen Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2013172954-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC (US) | 2013-11-21 | — | — | WO | claimed |
| WO-2012125973-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2012-09-20 | — | — | WO | claimed |
| US-20100240070-A1 | Nonseparation Assay Methods Using Peroxide Generating Enzymes | BECKMAN COULTER, INC. (US) | 2010-09-23 | — | — | US | claimed |
| WO-2006108686-A2 | BNP AGONISTS | AIC (BE) | 2006-10-19 | — | — | WO | claimed |
| EP-0920504-B1 | CLASS E VOLTAGE-GATED CALCIUM CHANNEL ANTAGONIST AND METHODS | ELAN PHARM INC (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1307217-A2 | VIP-RELATED PEPTIDES FOR THE TREATMENT OF SKIN DISORDERS | YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. (IL) | 2003-05-07 | — | — | EP | claimed |
| WO-2001093889-A2 | VIP-RELATED PEPTIDES FOR THE TREATMENT OF SKIN DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | GSR 4637/4885ARG2 4496/4885ARG1 4225/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | GSR 4728/4885ARG2 619/4885ARG1 472/4885 |
| US-20160304570-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | GSR 4637/4885ARG2 4496/4885ARG1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.